Bernard MaillÃ¨re

List of Publications by Year
in descending order

58 papers	1,692 citations	304602 22 h-index	302012 39 g-index
60 all docs	60 docs citations	60 times ranked	1764 citing authors

#	Article	IF	Citations
1	Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells. Frontiers in Immunology, 2022, 13, 808606.	2.2	7
2	Large-scale mapping of the Ebola NP and GP proteins reveals multiple immunoprevalent and conserved CD4 T-cell epitopes. Cellular and Molecular Immunology, 2021, 18, 1323-1325.	4.8	2
3	An antibody targeting type III secretion system induces broad protection against Salmonella and Shigella infections. PLoS Neglected Tropical Diseases, 2021, 15, e0009231.	1.3	4
4	Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses. Frontiers in Immunology, 2021, 12, 637963.	2.2	8
5	Impact of human sequences in variable domains of therapeutic antibodies on the location of CD4 T-cell epitopes. Cellular and Molecular Immunology, 2020, 17, 656-658.	4.8	14
6	Specificity of the T Cell Response to Protein Biopharmaceuticals. Frontiers in Immunology, 2020, 11, 1550.	2.2	15
7	Human Epitopes Identified from Herpes Simplex Virus Tegument Protein VP11/12 (UL46) Recall Multifunctional Effector Memory CD4⁺T_{EM}Cells in Asymptomatic Individuals and Protect from Ocular Herpes Infection and Disease in â€œHumanizedâ€•HLA-DR Transgenic Mice. Journal of Virology, 2020, 94, .	1.5	7
8	Healthy Donors Exhibit a CD4 T Cell Repertoire Specific to the Immunogenic Human Hormone H2-Relaxin before Injection. Journal of Immunology, 2019, 202, 3507-3513.	0.4	6
9	Fab is the most efficient format to express functional antibodies by yeast surface display. MAbs, 2018, 10, 720-729.	2.6	23
10	The ADAMTS13 ^{1239â€“1253} peptide is a dominant HLA-DR1-restricted CD4 ⁺ T-cell epitope. Haematologica, 2017, 102, 1833-1841.	1.7	14
11	CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naÃ¯ve and memory cells. Blood Advances, 2017, 1, 1842-1847.	2.5	32
12	Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors. Frontiers in Immunology, 2017, 8, 500.	2.2	69
13	Bioinspired Design and Oriented Synthesis of Immunogenic Site-Specifically Penicilloylated Peptides. Bioconjugate Chemistry, 2016, 27, 2629-2645.	1.8	9
14	The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer Donors. Journal of Immunology, 2015, 195, 1891-1901.	0.4	14
15	Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax, 2014, 69, 335-345.	2.7	13
16	Human CD4+ T Cell Responses to the Dog Major Allergen Can f 1 and Its Human Homologue Tear Lipocalin Resemble Each Other. PLoS ONE, 2014, 9, e98461.	1.1	11
17	Human CD4 T cell epitopes selective for Vaccinia versus Variola virus. Molecular Immunology, 2013, 53, 453-459.	1.0	5
18	Hierarchy of CD4 T Cell Epitopes of the ANRS Lipo5 Synthetic Vaccine Relies on the Frequencies of Pre-Existing Peptide-Specific T Cells in Healthy Donors. Journal of Immunology, 2013, 190, 5757-5763.	0.4	17

#	Article	IF	Citations
19	The Signal Peptide of the Tumor-shared Antigen Midkine Hosts CD4+ T Cell Epitopes. Journal of Biological Chemistry, 2013, 288, 13370-13377.	1.6	12
20	Comment on â€œThe Role of Naive T Cell Precursor Frequency and Recruitment in Dictating Immune Response Magnitudeâ€•. Journal of Immunology, 2013, 190, 1895-1895.	0.4	3
21	Bee Venom Phospholipase A2, a Good â€œChauffeurâ€•for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1. PLoS ONE, 2013, 8, e67645.	1.1	12
22	Development of a Humanized HLA-A2.1/DP4 Transgenic Mouse Model and the Use of This Model to Map HLA-DP4-Restricted Epitopes of HBV Envelope Protein. PLoS ONE, 2012, 7, e32247.	1.1	21
23	CD4⁺Tâ€cell immunity to theBurkholderia pseudomalleiABC transporter LolC in melioidosis. European Journal of Immunology, 2011, 41, 107-115.	1.6	8
24	Quantitative analysis of the CD4 Tâ€cell repertoire specific to therapeutic antibodies in healthy donors. FASEB Journal, 2011, 25, 2040-2048.	0.2	55
25	Epitope Hierarchy of Spontaneous CD4+ T Cell Responses to LAGE-1. Journal of Immunology, 2011, 186, 312-322.	0.4	7
26	Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood, 2010, 116, 4542-4545.	0.6	45
27	Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity. Protein Science, 2009, 13, 2970-2978.	3.1	22
28	In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R. Molecular Immunology, 2009, 46, 1481-1487.	1.0	14
29	3-Layer-based analysis of peptideâ€“MHC interaction: In silico prediction, peptide binding affinity and T cell activation in a relevant allergen-specific model. Molecular Immunology, 2009, 46, 1839-1844.	1.0	43
30	Suboptimal recognition of a T cell epitope of the major dog allergen Can f 1 by human T cells. Molecular Immunology, 2009, 46, 3320-3327.	1.0	10
31	Immunoprevalence of the CD4⁺ Tâ€cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively. European Journal of Immunology, 2008, 38, 2821-2831.	1.6	12
32	Dissociation between Epitope Hierarchy and Immunoprevalence in CD8 Responses to Vaccinia Virus Western Reserve. Journal of Immunology, 2008, 180, 7193-7202.	0.4	67
33	Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients. Journal of Immunology, 2008, 181, 431-439.	0.4	37
34	Characterization of HLA Class II/Peptide-TCR Interactions of the Immunodominant T Cell Epitope in Art v 1, the Major Mugwort Pollen Allergen. Journal of Immunology, 2008, 181, 3636-3642.	0.4	21
35	Gender-Dependent HLA-DR-Restricted Epitopes Identified from Herpes Simplex Virus Type 1 Glycoprotein D. Vaccine Journal, 2008, 15, 1436-1449.	3.2	61
36	HLA-DR-Restricted Peptides Identified in The Nef Protein Can Induce HIV Type 1-Specific IL-2/IFN-Î³-Secreting CD4+And CD4+/CD8+T Cells in Humans after Lipopeptide Vaccination. AIDS Research and Human Retroviruses, 2007, 23, 427-437.	0.5	14

#	Article	IF	Citations
37	Cross-Reactive CD4+ T Cells against One Immunodominant Tumor-Derived Epitope in Melanoma Patients. Journal of Immunology, 2007, 179, 7932-7940.	0.4	10
38	Determination of a HLA II Promiscuous Peptide Cocktail as Potential Vaccine Against EBV Latency II Malignancies. Journal of Immunotherapy, 2007, 30, 215-226.	1.2	24
39	Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins. European Journal of Immunology, 2007, 37, 1513-1523.	1.6	23
40	Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope. Hepatology, 2007, 45, 1199-1209.	3.6	26
41	Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunology, Immunotherapy, 2007, 56, 807-818.	2.0	19
42	Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers. Journal of Immunology, 2006, 177, 2717-2727.	0.4	16
43	Scanning the HIV Genome for CD4+ T Cell Epitopes Restricted to HLA-DP4, the Most Prevalent HLA Class II Molecule. Journal of Immunology, 2006, 176, 5401-5408.	0.4	21
44	A Truncated Alternative Spliced Isoform of Human Desmoglein 1 Contains a Specific T Cell Epitope Binding to the Pemphigus Foliaceus-Associated HLA Class II DRÎ²1*0102 Molecule. Journal of Immunology, 2006, 177, 6517-6526.	0.4	17
45	One NY-ESO-1-Derived Epitope That Promiscuously Binds to Multiple HLA-DR and HLA-DP4 Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma. Journal of Immunology, 2005, 174, 1751-1759.	0.4	64
46	Selective Modulation of CD4+ T Cells from Lupus Patients by a Promiscuous, Protective Peptide Analog. Journal of Immunology, 2005, 175, 5839-5847.	0.4	60
47	T Cell Epitope-Containing Peptides of the Major Dog Allergen Can f 1 as Candidates for Allergen Immunotherapy. Journal of Immunology, 2005, 175, 3614-3620.	0.4	37
48	Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA2as a membrane-binding vector. FEBS Letters, 2005, 579, 1658-1664.	1.3	10
49	A MAGE-3 Peptide Presented by HLA-DR1 to CD4+T Cells That Were Isolated from a Melanoma Patient Vaccinated with a MAGE-3 Protein. Journal of Immunology, 2003, 171, 219-225.	0.4	43
50	CD4+ T Cells from (New Zealand Black Ã— New Zealand White)F1 Lupus Mice and Normal Mice Immunized Against Apoptotic Nucleosomes Recognize Similar Th Cell Epitopes in the C Terminus of Histone H3. Journal of Immunology, 2003, 171, 636-644.	0.4	33
51	CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood, 2003, 101, 1351-1358.	0.6	114
52	HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity. Journal of Immunology, 2002, 169, 6928-6934.	0.4	103
53	Emerging principles for the design of promiscuous HLA-DR-restricted peptides: an example from the major bee venom allergen. European Journal of Immunology, 2002, 32, 3699-3707.	1.6	11
54	NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Research, 2002, 62, 213-8.	0.4	91

#	Article	IF	Citations
55	Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. European Journal of Immunology, 2001, 31, 1837-1846.	1.6	59
56	HLA-DR Restricted Peptide Candidates for Bee Venom Immunotherapy. Journal of Immunology, 2000, 164, 3177-3184.	0.4	131
57	On the diversity and heterogeneity of H-2d-restricted determinants and T cell epitopes from the major bee venom allergen. International Immunology, 1999, 11, 1313-1326.	1.8	16
58	Fine chemical modifications at N- and C-termini enhance peptide presentation to T cells, by increasing the lifespan of both free and MHC-complexed peptides. Molecular Immunology, 1995, 32, 1377-1385.	1.0	27